Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Shy Therapeutics LLC has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution profile is highly concentrated, involving 1 distinct examiner and 1 distinct art unit. This indicates that the company's current patenting efforts are focused on a specific biological or pharmaceutical innovation within a single technical division. The concentration in 1 distinct art unit suggests that the subject matter is specialized and does not span multiple biotechnology disciplines.
MCKOY, QUINCY ANDRE is the busiest examiner for the portfolio, holding 1 busiest examiner pending action. Because the total pending office actions and the busiest examiner pending count are each 1, this examiner is the only official currently reviewing the company's active applications. The presence of only 1 distinct examiner means that the outcome of the portfolio's current prosecution phase depends on the interactions with this official. Practitioners should analyze the historical allowance rates of MCKOY, QUINCY ANDRE to better manage the prosecution of this single pending matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCKOY, QUINCY ANDRE | 1 | 68.4% | +39.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18010697 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | MCKOY, QUINCY ANDRE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18010697 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | MCKOY, QUINCY ANDRE | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18010697 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | MCKOY, QUINCY ANDRE | 1626 | §102§103§112Other | Non-Final OA | — | Pending | Dec 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShy Therapeutics LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Quincy Andre Mckoy has the most, with 1 of Shy Therapeutics LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
